Liberty Research, Inc.

Company Overview

Liberty Research, Inc. is a privately held animal testing and breeding company headquartered in Waverly, Tioga County, New York. The company holds both a USDA Class A dealer license (breeder) and a Class R research registration, making it one of a small number of U.S. facilities authorized to both breed purpose-bred laboratory animals and conduct regulated research studies on the same premises.

The facility is located in a rural area near the Pennsylvania border in New York's Southern Tier region. Liberty has maintained a deliberately low public profile for decades, with no corporate website and minimal public filings beyond what USDA licensing requires. The company's operations came to broader public attention only after the 2017 PETA investigation.

Beagle Operations & Business Model

Liberty's dual-license structure enables a business model that most other industry participants keep separated. The typical industry arrangement involves purpose-bred beagles flowing from breeders (Marshall, Ridglan, Envigo) to contract research organizations (Charles River, Labcorp, Inotiv) where testing is performed on behalf of pharmaceutical sponsors. Liberty collapses this two-step supply chain into a single operation.

The company breeds beagles on site, maintains a colony for its own contract studies, and sells surplus animals to external research clients. This vertical integration gives Liberty control over the animals from birth through study completion — reducing transportation costs and acclimation periods, but also concentrating breeding, housing, and experimental procedures within one facility under one management team.

Unique Industry Position

Liberty's combined breeder-and-tester model is rare in the U.S. animal research supply chain. Most major players occupy one side of the transaction:

This integration means Liberty's animals may never leave the facility from birth to study endpoint. For pharmaceutical sponsors, it offers convenience and lower costs. For oversight, it creates a closed loop that makes external monitoring more difficult.

The Intercept Investigation (2018)

On May 17, 2018, The Intercept published a major investigative feature titled “Inside the Barbaric U.S. Industry of Dog Experimentation” that placed Liberty Research within the broader context of the commercial beagle testing pipeline. The reporting identified Liberty as a facility that both breeds and sells dogs and cats to major pharmaceutical companies.

The article specifically named Merck, Zoetis, and Bayer as pharmaceutical companies receiving animals from or contracting studies through Liberty. This established direct supply-chain links between one of the industry's least transparent facilities and some of the world's largest animal health and pharmaceutical corporations.

The Intercept's reporting drew on records obtained through FOIA requests, undercover footage, and interviews with current and former industry workers. It described the beagle testing industry as a “barbaric” system operating largely out of public view in rural communities across the eastern United States.

USDA Inspection & Enforcement History

Liberty Research holds dual USDA licenses and is therefore subject to inspection under the Animal Welfare Act. However, the facility's enforcement record stands in sharp contrast to the conditions documented by the 2017 investigation.

Despite the PETA exposé generating significant media coverage and public concern, USDA has not pursued enforcement action against Liberty comparable to what was eventually taken against Envigo ($35M+ penalty, 4,000 dogs seized) or even the state-level actions that Ridglan Farms has faced in Wisconsin.

Community & Public Opposition

Waverly is a small village in Tioga County, New York, near the Pennsylvania state line. Like many rural communities hosting animal testing or breeding facilities, Waverly has a complex relationship with Liberty Research. The company provides local employment in an area with limited economic alternatives, creating a dynamic where residents may be reluctant to challenge a significant employer.

Following the 2017 PETA investigation, local and regional animal advocacy groups organized protests and called for increased oversight. The investigation generated coverage in regional outlets and national animal welfare media, though sustained local organizing has been limited compared to campaigns against facilities like Envigo (which benefited from direct Congressional involvement by Virginia senators) or Ridglan (which faced a multi-year community-driven complaint campaign).

National organizations including PETA and the Humane Society of the United States have referenced Liberty in broader campaigns against beagle testing, but the facility has not become the sustained focus of a single-target campaign in the way that Envigo, Marshall, and Ridglan have.

Key People

Liberty Research maintains a very low public profile. Corporate leadership and ownership information is not readily available through standard public databases.

Pharmaceutical Clients

The Intercept's 2018 reporting identified three major pharmaceutical companies as having commercial relationships with Liberty Research:

Additional clients likely exist but have not been publicly identified. Liberty's dual role as both breeder and contract research facility means clients may purchase animals, commission studies, or both.

Timeline

Enforcement Comparison

Liberty's trajectory compared to other investigated facilities underscores the inconsistency of AWA enforcement: